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Abstract
Background: Recent advances in understanding molecular and synaptic mechanisms of intellectual disabilities (ID)
in fragile X syndrome (FXS) and Down syndrome (DS) through animal models have led to targeted controlled trials
with pharmacological agents designed to normalize these underlying mechanisms and improve clinical outcomes.
However, several human clinical trials have failed to demonstrate efficacy of these targeted treatments to improve
surrogate behavioral endpoints. Because the ultimate index of disease modification in these disorders is amelioration of
ID, the validation of cognitive measures for tracking treatment response is essential. Here, we present preliminary
research to validate the National Institutes of Health Toolbox Cognitive Battery (NIH-TCB) for ID.
Methods: We completed three pilot studies of patients with FXS (total n = 63; mean age 19.3 ± 8.3 years, mean
mental age 5.3 ± 1.6 years), DS (n = 47; mean age 16.1 ± 6.2, mean mental age 5.4 ± 2.0), and idiopathic ID (IID;
n = 16; mean age 16.1 ± 5.0, mean mental age 6.6 ± 2.3) measuring processing speed, executive function, episodic
memory, word/letter reading, receptive vocabulary, and working memory using the web-based NIH-TB-CB, addressing
feasibility, test-retest reliability, construct validity, ecological validity, and syndrome differences and profiles.
Results: Feasibility was good to excellent (≥80 % of participants with valid scores) for above mental age 4 years for all
tests except list sorting (working memory). Test-retest stability was good to excellent, and convergent validity was
similar to or better than results obtained from typically developing children in the normal sample for executive
function and language measures. Examination of ecological validity revealed moderate to very strong correlations
between the NIH-TCB composite and adaptive behavior and full-scale IQ measures. Syndrome/group comparisons
demonstrated significant deficits for the FXS and DS groups relative to IID on attention and inhibitory control, a
significant reading weakness for FXS, and a receptive vocabulary weakness for DS.
Conclusions: The NIH-TCB has potential for assessing important dimensions of cognition in persons with ID, and
several tests may be useful for tracking response to intervention. However, more extensive psychometric studies,
evaluation of the NIH-TCB’s sensitivity to change, both developmentally and in the context of treatment, and perhaps
establishing links to brain function in these populations, are required to determine the true utility of the battery as a set
of outcome measures.
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Background
Although intellectual disability (ID) has been considered
to be lifelong, with little promise for meaningful recovery
of cognitive functions, recent advances in understanding
of underlying genetic and neurobiological abnormalities of
syndromic forms of several disorders, as well as progress
in translation of targeted pharmacological and behavioral
treatments, suggest that substantial cognitive gains may
be possible and contribute to meaningful improvements
in daily functioning and independence. Despite these
exciting developments, there is little consensus on how
cognitive improvements should be objectively measured.
This paper presents preliminary research efforts to estab-
lish and validate the National Institutes of Health Toolbox
Cognitive Battery (NIH-TCB) for individuals with ID, with
a primary focus on its use as a series of cognitive end-
points for targeted pharmacological trials and other inter-
vention studies.
An ID is a disability, originating before the age of 18,
characterized by significant limitations in both intellec-
tual functioning (typically IQ < 70) and adaptive behavior
as expressed in conceptual, social, and/or practical skills
(American Association of Intellectual and Developmen-
tal Disabilities; www.aaidd.org). ID is heavily represented
in a wide range of neurodevelopmental disorders (NDD),
including Down syndrome (DS), fetal alcohol syndrome,
autism spectrum disorder (ASD), tuberous sclerosis, fra-
gile X syndrome (FXS), Rett syndrome, and many other
genetic conditions and syndromes with a spectrum of
etiologies yet to be identified (idiopathic ID). In ASD,
estimated to affect 1 in 88 children by the Centers
for Disease Control (CDC), a meta-analysis of studies
revealed a rate of ID as high as 75 % [1]; although
more recent large-scale epidemiological studies reflect
a rate of approximately 41 %.
Recent advances in understanding the molecular mech-
anisms underlying NDD through animal models [2–5]
have led to targeted controlled trials with pharmacological
agents designed to normalize molecular abnormalities,
synaptic function, cognition, and behavior in humans with
these conditions. FXS, the most common inherited form
of ID, is by far the leading example of this translational
effort. The disorder is caused by a mutation in a gene
(fragile X mental retardation 1 or FMR1) on the long
arm of the X chromosome, leading to the absence or
reduction of its protein product, fragile X mental re-
tardation 1 protein (FMRP). Lack of FMRP leads to
abnormalities in dendritic structure and synaptic plasti-
city, as well as functional and structural brain abnormal-
ities, and a cognitive phenotype characterized by deficits
in executive function, including working memory [6, 7],
inhibitory control [6–9], cognitive flexibility/perseveration
[9], and selective and divided attention [9–11]; verbal
short-term memory [10]; visuospatial memory [10]; pro-
cessing of sequential and abstract information [12]; arith-
metic reasoning [13–15]; and all domains of expressive
and receptive language, most notably syntactic and prag-
matic domains [16].
Extensive studies with two FXS animal models, the
fmr1 knockout mouse and dfmr Drosophila (fruit fly)
mutant, have demonstrated abnormalities in metabotropic
glutamate (mGluR) [3] and γ-aminobutyric acid (GABA)
[17] receptor signaling due to loss of normal inhibitory
control of dendritic translation in the absence of FMRP.
In both models, numerous cognitive, behavioral, electro-
physiologic, and morphologic (dendritic spine) phenotypes
are normalized with mGluR5-negative modulators and
GABA agonists. These discoveries paved the way for ex-
perimental treatment of the underlying neurobiology of the
disorder in humans, including nine (to date) placebo-
controlled, randomized trials of mGluR5-negative modula-
tors (Roche—two phase 2a trials and a phase 2b trial;
Novartis—a phase 2a [18] and two phase 2b trials [19]) and
a GABA-B agonist (Arbaclofen, Seaside Therapeutics—a
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phase 2 trial [20] and two phase 3 trials in adults/adoles-
cents and children [21]).
Despite substantial international efforts to evaluate the
efficacy of these targeted treatments in adults and ado-
lescents with FXS, the trials did not demonstrate signifi-
cant clinical benefits based on the primary behavioral
endpoints. Despite some promising positive indicators of
improvement on the secondary outcome measures [20]
or in post hoc analyses of potentially meaningful clinical
subgroups [18], these trials were deemed “negative” or
“failed” and none of these companies have been able to
continue a FXS program. Given the overwhelming suc-
cess with the animal models, the negative outcomes of
human trials have been disheartening to families and
have been a surprising and sobering call to investigators
to better understand the limitations of the trials and to
develop better designed studies with more sensitive out-
come measures. Although ID is the hallmark feature of
FXS, cognitive measures were not used to track treat-
ment response, mainly due to a lack of consensus about
which measures to choose, a lack of validation of exist-
ing measures in ID and/or FXS that could quantify
short-term changes in cognition, and a desire to reduce
distressing maladaptive behaviors which are typically of
primary concern to caregivers [22–24].
DS is another neurodevelopmental disorder with prom-
ising therapeutic targets based on animal studies. DS is
due to the presence of an extra copy of chromosome 21
(i.e., trisomy 21). The condition is relatively common, with
an incidence of 1:1000 live births [25]. People with DS
typically demonstrate deficits involving learning, memory,
language, and movement. Most individuals with DS fall
into the mild-to-moderate range of ID and have IQs com-
parable to males with FXS. The cognitive phenotype is
characterized by deficits in verbal working memory and
recall [26], cognitive flexibility [27–29], visual memory
and learning [28, 30, 31], and planning and goal-directed
problem-solving [32–34]. Deficits in the hippocampal and
frontal systems involving memory and executive function-
ing are especially marked.
Development of a targeted treatment for individuals
with DS has come from work with the Ts65Dn mouse
model. The mice have segmental trisomy for a portion
of mouse chromosome 16 that is orthologous to the
long arm of human chromosome 21. Ts65Dn mice, like
humans with DS, have profound deficits in memory and
learning and demonstrate excessive inhibition (deficient
long-term potentiation (LTP)) in the dentate gyrus. In
the DS mouse model, cognitive deficits in object and
declarative memory, as well as LTP deficits, are reversed
with inverse agonists of alpha5 subunit-containing
GABAA receptors, leading to the use of these agents in
human trials of DS [5, 35]. A phase 1b trial of RG1662
(Roche) for cognitive function in DS adults has been
completed, and phase 2 trials in adults and children are
in progress (clinicaltrials.gov; NCT02024789).
These early trials have generated an urgent need to
develop and validate cognitive tools for tracking treat-
ment response in ID for several reasons. First, parent
ratings in the above-referenced FXS trials were affected
by high placebo response rates (10–40 % improvement
in baseline scores [19–21]) which substantially under-
mined the power to detect actual therapeutic benefits. In
contrast, cognitive measures are a more direct assessment
of performance and are less subject to placebo effects.
Second, measures that are as close to the underlying
neurobiological abnormalities of the disorder as possible
are most desirable. Although it is possible to identify
behaviors that are characteristic of the FXS phenotype,
problematic behaviors are greatly affected by ongoing
interaction with variations in the person’s environment
(e.g., parenting, physical and social environment, re-
sponses to behaviors [36]). Cognition is likely to be
affected by environmental factors as well but may be less
prone to these confounds and better reflect true brain
functional differences associated with neurobiology. Third,
it is likely that some cognitive functions will respond to
treatment more quickly than behavior or that the methods
of cognitive assessment (error rate, response time) are
more sensitive to positive changes in the brain’s capacity
to attend to, process, and respond to information.
Many standardized cognitive measures (e.g., Wechsler
Intelligence and Memory Scales, NEPSY-II, Leiter-R)
appear to have face validity and utility for ID, but im-
portant limitations prevent them from being used as
outcome measures in clinical trials. First, when these
tests are given to individuals with ID, standardized
scores (and often raw scores) are at or near the floor of
the test range, severely limiting sensitivity [37, 38]. Sec-
ond, many cognitive tests are developed to assess an in-
dividual’s abilities at a given time point for clinical
assessment but are not suitable as clinical trial outcome
measures due to lack of stability, practice effects, or
lack of sensitivity to change during the treatment
period. Third, lack of consensus on the best measures
of cognition for persons with ID has led investigators to
choose a wide variety of tests as outcome measures,
often without knowledge of their psychometric proper-
ties (feasibility, reliability, validity) in persons with ID.
This makes meaningful comparisons across studies and
interventions, within and across disorders, difficult or
impossible. Fourth, most measures do not demonstrate
an association with real-life outcomes, such as adaptive
behavior or functional skills. The validation of measures
vis-à-vis functional outcomes is an important aspect in
evaluating the results of clinical trials and labeling
claims from the FDA perspective. Fifth, the broad range
of severity of ID and high rate of behavioral and
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emotional disturbances make reliable and valid assessment
difficult. Special and standardized procedures for handling
these issues are likely to be essential in most studies but
are rarely addressed, documented, or reported.
The NIH-TCB, a component of the NIH Toolbox for
Assessment of Neurological and Behavioral Function, was
developed to standardize evaluations in specific clinical
populations for investigations of neurological development
and change, disease recovery, and therapeutic interven-
tions (www.nihtoolbox.org; [39, 40]). The NIH-TCB is a
battery of extensively validated computer-administered
cognitive tests with utility across childhood and adoles-
cence, early adulthood, and old age. The NIH-TCB
assessments were designed to minimize floor and ceiling
effects which often are present in testing batteries designed
for the general population. Therefore, there was good
reason to believe that the assessments would be
appropriate for individuals with ID. The initial validation
study of 475 participants between 3 and 89 years, includ-
ing 208 children, was completed several years ago [41].
The entire range of instruments, scoring criteria, and nor-
mative data from a randomly selected and stratified sample
of 4500 individuals in the USA in this age range are now
available. Recently, the NIH-TCB has been adapted for use
on the iPad by the National Children’s Study to follow the
development of children ages 3–21 years and their parents,
and several of the subtests now have a developmental ex-
tension option to age 2. Despite its extensive development
and validation in the general population, the NIH-TCB
had not been evaluated for feasibility, reliability, validity, or
sensitivity to change in individuals with ID.
Here, we report our experience with the NIH-TCB in
three pilot studies of individuals with ID, focusing pri-
marily on feasibility and identification of modifications
that may be needed for ID populations (advantages and
limitations for each test), as well as preliminary validity,
reliability, and cross-syndrome comparisons. Three stud-
ies are presented together in sequential fashion in order
to illustrate the progression, iterative process, and psy-
chometric work involved in developing and validating
cognitive outcome measures for atypical populations.
The first study focused on feasibility in 31 patients with
FXS utilizing earlier versions of two executive function
tasks (flanker and dimensional change card sort, using
keyboard responses) made available before the NIH-TCB
was complete. The second study focused on 22 patients
with FXS and 28 with DS, included all tests in the NIH-
TCB, used Windows-based touch screen technology as
employed in the standardization samples, and examined
feasibility, test-retest reliability, and cross-syndrome
comparisons. Finally, the third study, a pilot project
within the first year of the multi-site funded grant “A
Cognitive Test Battery for Intellectual Disabilities”
(R01HD076189) progressed to use of the newly released
tablet versions of the battery in 45 patients with ID (19
DS + ID, 10 FXS + ID, and 16 idiopathic ID (IID)), in-
cluding examination of reliability and enhanced validity
tests. Feasibility was further explored in developmental
extensions of two NIH-TCB tasks and potential modifi-
cations of cross-validation measures.
Materials and methods
Participants
For study 1, to establish the initial feasibility of the NIH-
TCB for individuals with ID, P. Zelazo shared two of the
measures, flanker and dimensional change card sort
(DCCS) [42] for pilot testing. These tests were adminis-
tered to 31 patients with FXS [20 at UC Davis, 11 at Rush
University Medical Center (RUMC); 27 males] between
the ages of 5 and 36 years (mean = 19.3). Participants were
recruited from fragile X clinics or from screening visits for
clinical trials. The mean full-scale IQ (i.e., Stanford-Binet
5, Wechsler Scale, or Leiter-R) was 47.2 ± 16.1 and mean
mental age was 5 years and 2 months with a range of
2 years and 1 month to 8 years and 0 months.
For study 2, participants included 22 patients with
FXS (16 males; mean age 19.6 years, range 4.5–36.6)
and 28 with DS (15 males; mean age 16.3 years, range
6.0–27.0). These individuals were all assessed at RUMC
and recruited from the fragile X clinic or the Chicago
area UPS for DownS family support organization. Men-
tal age (measured from IQ testing or estimated by clini-
cians based on chart review, school records, and parent
report of functioning) ranged from 2 to 10 years (mean
4.9 ± 2.0). Participants with FXS were on average 2 years
lower (p < .001) on mental age than those with DS (5.9 vs.
3.7 years, respectively). In study 2, full-scale IQ (combined
across available tests) ranged from 30 to 82 (mean 50.63 ±
13.7) and adaptive behavior (Vineland Adaptive Behavior
Scales, Second Edition) composite scores ranged from 20
to 88 (mean 62.4 ± 19.8); however, these assessments were
available on just 27 of the 50 participants.
For study 3, participants included 45 patients with ID
[19 patients with DS, 10 patients with FXS, 16 patients
with IID; 20 seen at UC Davis, 10 at University of Denver
(DU), and 15 at RUMC], each with ID or borderline ID
according to the Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5) criteria (defined
by a Stanford-Binet 5 full-scale IQ of <80) and impair-
ments in adaptive behavior as measured by the Vineland
Adaptive Behavior Scales. These participants were re-
cruited from fragile X clinics at each site, DS and FXS sup-
port groups, research participant registries, special events
for persons with developmental disabilities, and from no-
tices distributed by family support foundations. In this
study, all participants had a mental age of 3 years or
higher, a chronological age between 6 and 25 years, no un-
corrected vision or hearing impairments, no history of
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head trauma or other medical condition other than ID af-
fecting cognition, and at least short-phrase speech with
English as their primary language. Participants had a mean
IQ of 51.3 ± 11.8, a mean chronological age of 15.8 ±
5.7 years, a mean mental age of 5.3 ± 2.0 years, and a
adaptive behavior composite of 60.9 ± 17.0. The protocols
for the studies received prior approval by the Institutional
Review Boards at UC Davis, RUMC, and DU, and in-
formed consent was obtained from each participant or
their legal guardian.
NIH-TCB measures
A thorough description of the NIH-TCB, including the
rationale for test selection, neuroanatomical basis, and
psychometric properties in a large representative sam-
ple of individuals from ages 3 to 89, are found in
Weintraub et al. [39]. Additional details of the battery
as specifically relevant to the pediatric population are
found in Weintraub et al. [43].
Dimensional change card sort test
DCCS [44] is a measure of cognitive flexibility. Two tar-
get pictures are presented that vary along two dimen-
sions (i.e., shape and color). Participants are asked to
match a series of bivalent test pictures (e.g., yellow balls
and blue trucks) to the target pictures, first according to
one dimension (e.g., color) and then, after a number of
trials, according to the other dimension (e.g., shape).
“Switch” trials are also employed, in which the partici-
pant must change the dimension being matched. For ex-
ample, after four trials matching on shape, the
participant is asked to match on color on the next trial
and then switch back to matching by shape. Scoring is
based on a combination of accuracy and reaction time
(computed score, ranging from 0 to 10), and the test
duration is about 4 min. Recent versions of this task in-
clude a developmental extension designed to extend the
range of the assessment downward for those who find
the original task difficult to understand. For example,
participants are asked to match an image to one of two
choices in which one is clearly similar and the other
image is very different.
Flanker inhibitory control and attention test
Flanker [44] is a measure of inhibition and visual atten-
tion. On each trial, a central directional target (fish for
mental age younger than 8, arrows for ages 8 and older)
is flanked by similar stimuli on the left and right. The
participant chooses the direction of the central stimulus.
On congruent trials, the flankers face the same direction
as the target. On incongruent trials, they face the oppos-
ite direction. A scoring algorithm integrates accuracy, a
suitable measure in early childhood/low mental ages,
and reaction time, a measure more relevant to adult
performance on this task, yielding computed scores from
0 to 10. There are 40 trials, and the test duration is
about 4 min. This task also has a developmental exten-
sion. In the extension, participants begin by simply
choosing the direction a single large fish is facing. The
task becomes progressively more difficult by adding
flanking fish of differing sizes and colors.
Picture sequence memory test (episodic memory)
Picture Sequence Memory [45] involves recalling in-
creasingly lengthy series of illustrated objects and activ-
ities around different themes (e.g., “playing at the park,”
“working on the farm”) that are presented in a particular
order on the screen. For each trial, pictures appear in
the center of the computer screen and then are moved
one at a time into a fixed spatial order, as an audio file
simultaneously describes the content of each (e.g., “Plant
the tomatoes”), until the entire sequence is displayed on
the screen. Then, the pictures return to the center of the
screen in a random display and the participant moves
them into the sequence that was shown. The score is de-
rived from the cumulative number of adjacent pairs of
pictures remembered correctly over 2–3 learning trials.
Level of task difficulty is adjusted for the various age
groups. Administration time is about 10 min. Theta
scores are used for this test. Note that in study 2, the
same form was used in test and retest, whereas in study
3, test-retest reliability of alternate forms A and B (dif-
ferent themes) was examined (randomized order). (In
the normative studies, forms A and B were evaluated,
and then scores adjusted for statistical equivalency using
randomly equivalent cross-sectional administration.
Score adjustments are applied depending on age group
(e.g., ages 5–7, 8–59, 60+). No score adjustment was ne-
cessary for the 3–4 age group.)
List sorting working memory test
List Sorting [46] requires immediate recall and sequen-
cing of different visually and orally presented stimuli.
Pictures of different foods and animals are displayed
with accompanying audio recording and written text
(e.g., “elephant”), and the participant is asked to state the
items in size order from smallest to largest, first within a
single dimension (either animals or foods) and then on
two dimensions (first foods, then animals). The raw
score is the number of items recalled and sequenced
correctly, and the test duration is about 7 min.
Pattern comparison processing speed test
Pattern Comparison [47] measures the speed of process-
ing by asking participants to discern whether two side-
by-side pictures are the same or not the same by touch-
ing “yes” or “no” (or a happy or frowning face for lower
mental age). The raw score is the number of items
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correct in a 90 s period. The items are designed to be
simple to distinguish. The test duration is about 3 min.
Oral reading recognition test
For Oral Reading [48], the participant is asked to read
and pronounce letters and words as accurately as pos-
sible. The items are administered by computer adaptive
testing (CAT; continuously adapted depending on per-
formance), and participant responses are scored by the
examiner. For the youngest children, the initial items re-
quire identification of letters (as opposed to symbols)
and identification of a specific letter within an array of
four symbols. The test duration is about 3 min. A theta
score is calculated for this test.
Picture vocabulary test
Picture Vocabulary [48] is a measure of receptive vo-
cabulary administered in a CAT format. The participant
is presented with an audio recording of a word and four
photographs on the screen and is asked to select the pic-
ture that most closely matches the meaning of the word.
This test duration is about 4 min. A theta score is used
for this test.
Prior to the initiation of data collection, the research
coordinator from each testing site was trained remotely
by staff members from the NIH Toolbox Project at
Northwestern University. The coordinators then trained
all examiners at each site. Note that in studies 2 and 3,
the starting points for each NIH-TCB test was based on
each participant’s mental age rather than chronological
age. All NIH-TCB tests have manualized instructions to
ensure fidelity in administration and a set of practice
items to aid participants in understanding and ensure
compliance (see nihtoolbox.org). The website also in-
cludes technical manuals for each test covering valid-
ation, norming, and scoring algorithms.
Concurrent validation measures (study 3)
See Table 1 for a list of NIH-TCB constructs and conver-
gent validity measures chosen for study 3.
Kiddie Test of Attention Performance
The Kiddie Test of Attention Performance (KiTAP; [49])
is an executive function battery comprised of eight sub-
tests designed around an enchanted castle theme specif-
ically designed to be accessible to young children. Based
on our prior work on the feasibility, reliability, and valid-
ity of the KiTAP in FXS [49], we chose the flexibility,
go/no-go, and distractibility subtests, which include reli-
able and validated scores matching well with several
NIH-TCB constructs.
Peabody Picture Vocabulary Test, Fourth Edition
The Peabody Picture Vocabulary Test, Fourth Edition
(PPVT-4; [50]) is a norm-referenced test for measuring
the receptive vocabulary. For each item, the examiner
says a word, and the participant selects the picture that
best captures the word’s meaning. This test was
administered on a touch screen tablet and was chosen to
cross-validate the picture vocabulary test of the NIH-
TCB. The PPVT-4 also was used as a discriminant valid-
ity measure for several non-verbal NIH-TCB tasks, as it
was in the normative studies [48].
Table 1 Performance and parent-report observational (PRO) measures used for convergent validity by NIH-TCB construct in study 3
Construct Toolbox task Validation measures Type
Cognitive flexibility Dimensional charge card sort (DCCS) KiTAP flexibility: errors and median Rxn time Performance
BRIEF-preschool flexibility scale
BRIEF-school-age emotional control and shift scale
PRO
Inhibitory control and visual attention Flanker KiTAP go/no-go: errors, median, and SD Rxn time Performance
ABC hyperactivity subscale raw score PRO
BRIEF-preschool and school-age inhibit scale PRO
KiTAP distractibility: errors, median, and SD Rxn time Performance
SWAN attention subscale PRO
Receptive vocabulary Picture vocabulary PPVT-4 raw score Performance
Letter ID and word reading Oral reading WJ-4 letter/word ID raw score Performance
Episodic memory Picture sequence memory Leiter-R forward memory raw score Performance
Leiter-R spatial memory picture score Performance
Processing speed Pattern comparison KiTAP go/no-go: errors, median, and SD Rxn time Performance
Working memory List sorting SB-5 verbal working memory Performance
BRIEF-preschool and school-age working memory scale PRO
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Woodcock Johnson Tests of Achievement, Fourth Edition,
Letter/Word Identification Test
This is a measure of single word oral reading and letter
identification [51]. This test was chosen to cross-validate
the NIH-TCB oral reading test.
Leiter International Performance Test, Revised
Spatial memory [52]: This is a measure of visuospatial
memory. A matrix of child-friendly objects is displayed
for 10 s, and then removed. The participant is asked to
place the cards of the pictured objects in the correct
locations on a blank matrix. Forward memory [52]: this
is a measure of sequential memory span. The assessor
shows the participant a grid with child-friendly pictures
and taps the pictures in a specific order. The participant
is then asked to tap the pictures in the same order.
Stanford-Binet Intelligence Scale, Fifth Edition—block span,
verbal working memory index, and full-scale IQ
For block span [53], the participant watches the examiner
tap green cubes laid out in two rows on a page colored
red or yellow. For easier items, the participant taps the
blocks in the same sequence as the examiner, with in-
creasing spatial spans. For more difficult items, requiring
a higher working memory load, the participant observes
the examiner tap the blocks as before but must tap all the
blocks in one colored row in order first, followed by the
blocks in the other colored row in order. The verbal work-
ing memory index [53] has two types of test items, de-
pending on difficulty: memory for sentences and last
word. In memory for sentences, the participant repeats in-
creasingly complex sentences said aloud by the examiner.
In last word, the participant is read a series of from one to
nine questions depending on level. First, the participant
answers each question, and then, after all the questions,
recalls and states the last word in each question.
For the Stanford-Binet IQ scores, we followed z
deviation scoring methods described in detail in Sansone
et al. [38], which provides significantly greater sensitivity
and eliminates flooring in individuals in the low func-
tioning range.
Caregiver report measures
The Aberrant Behavior Checklist (ABC) [54] is a symptom
checklist for assessing problem behaviors of children and
adults with intellectual disabilities. It includes scores on
five subscales: irritability/agitation, lethargy/social with-
drawal, stereotypic behavior, hyperactivity/noncompliance,
and inappropriate speech. For this study, the ABC-
community was used. The Behavior Rating Inventory of
Executive Function (BRIEF) [55] is an 86-item parent or
teacher rating to assess executive function and self-
regulation in children and teenagers. Global executive
composite is the combination of the behavioral regulation
and metacognition indices. The strengths and weaknesses
of attention-deficit/hyperactivity disorder symptoms and
normal behavior scale (SWAN) [56] is an 18-item parent
questionnaire assessing the symptoms of attention-deficit/
hyperactivity disorder for children and adolescents.
In each study, NIH-TCB measures were administered
in a random order for each participant (DCCS and
flanker only in study 1 and all seven measures in studies
2 and 3). In most cases, participants were cooperative
and compliant during testing and responded to praise to
maintain motivation and attention; however, in some
cases, tangible rewards were used (e.g., a snack during a
break or a small gift following completion of the bat-
tery). In studies 1 and 2, general notes were taken during
test administrations to record behaviors or technical
problems that might invalidate test results. These proce-
dures were better standardized for study 3 and required
examiners to check each test as valid or to record the
reasons for invalid administration, which included when
the participant (a) needed excessive prompting; (b)
refused to be part of all of testing; (c) was unresponsive;
(d) had poor task understanding (as judged by the ability
to pass practice criteria and in some cases verbally
explain what they were asked to do); (e) technical diffi-
culties; (f ) participant ill/emergency; and (g) others.
These notes were later used to determine whether to
exclude particular data points for examination of test
feasibility and use in data analyses. For study 3, NIH-
TCB and validation measures were administered across
a 2-day period with frequent breaks to maximize com-
pliance and minimize fatigue. A visual schedule/story
board was used to increase structure, understanding,
and predictability of the testing process and motivation
in lower functioning participants (Fig. 1). The test-retest
interval for study 2 was 13–95 days (mean = 37 days)
and the interval for study 3 was 20–47 days (mean =
29 days). All data for study 3 was entered and managed
within the Research Electronic Data Capture (REDCap)
[57] system at UC Davis Clinical and Translational
Science Center (CTSC).
Data analyses
For analyses focused on test-retest reliability and conver-
gent/discriminant validity, we used the raw, computed,
and theta scores as described above for each test. In
order to compare and contrast NIH-TCB profiles within
and across diagnostic groups, we calculated age-
corrected z scores representing the deviation of each
participant’s performance on each test from the norma-
tive sample for his/her age (see [37, 38] for details of this
scoring method). We also applied this transformation
for the Stanford-Binet 5 IQ scores as previously de-
scribed [38]. In both cases, the deviation scoring method
is used to eliminate the flooring effects that are
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pervasive in the samples of individuals with ID when
scaled scores are used. We calculated the toolbox crys-
tallized composite (averaged from picture vocabulary
and oral reading), toolbox fluid reasoning composite (av-
eraged from DCCS, pattern comparison, list sorting,
flanker, and picture sequence memory), and toolbox cog-
nitive function composite (averaged crystallized and fluid
reasoning scores) as described by Akshoomoff et al. [58].
We required 1 of 2 crystallized reasoning tests and 4 of
5 fluid reasoning tests to generate composite scores in
these domains. Feasibility was calculated as the percent-
age of participants enrolled who completed each test
yielding valid data (as determined by observation of test-
ing by the examiner and the generation of a valid score).
Test-retest reliability was estimated using intraclass cor-
relation coefficients (ICC). Convergent and discriminant
validity were examined using Pearson’s or Spearman’s
correlations. NIH-TCB theta or raw scores were used to
calculate test-retest reliability and to correlate with
chronological and mental age and age-corrected devi-
ation scores to correlate with age-adjusted IQ and adap-
tive behavior scores. Group comparisons of NIH-TCB z
deviation scores were examined using ANOVA (col-
lapsed across studies 2 and 3) followed by testing a
priori contrasts based on the hypotheses of (a) greater
deficits in executive function and working memory in
FXS (compared to the other groups), (b) greater deficits
in the language and episodic memory in DS (compared
to the other groups), and (c) similar processing speed
across groups. Given that the three groups were not
equivalent on overall intelligence, we followed up with
analyses using IQ as a covariate. In study 3, psycho-
metric properties of the NIH-TCB in the ID samples
(feasibility, reliability, and validity) were compared
with those available from the pediatric sample (ages




All 31 patients with FXS in study 1 demonstrated the
ability to use the touch screen for response, and the ma-
jority expressed positive effect and showed interest in
use of this technology. A programming error resulted in
two administrations of flanker that were not usable. For
the remaining administrations, 24 of 29 (82.8 %) partici-
pants completed flanker and 83.8 % completed DCCS
with valid scores as defined by Zelazo et al. [44] in gen-
eral population studies (these rates were 89 and 90 % for
those with a mental age of >3 years). The remaining par-
ticipants either did not understand instructions adequate
to reach practice criterion or needed too many prompts
during testing to consider the results valid.
On flanker, participants made significantly more errors
and demonstrated longer reaction times for incongruent
Fig. 1 Story board/picture schedule used in study 3 to increase motivation and understanding of assessment visit schedule. The participant prize
or a representation of the prize for compliance and effort is placed in the center, and with the examiner’s assistance, the participant checks off
each completed task with a dry erase pen. NIH-TCB tasks from top (clockwise) depicted are flanker, dimensional change card sort, picture
sequence memory, picture vocabulary, oral reading, pattern comparison, and list sorting
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than congruent trials (59 vs. 80 % correct, p = .003; 2363
vs. 1889 ms, p = .002). On DCCS, participants made
more errors on trials involving a switch (change cogni-
tive set) than without a switch (66.2 vs. 82.0 % correct;
p < .001), although reaction times were not affected by
trial type. These data demonstrated that the tasks pro-
duced expected effects on executive function in this
sample. Flanker and DCCS scores demonstrated sub-
stantial range and variability, without flooring or ceiling,
and showed modest Spearman’s correlations with full-
scale IQ (flanker accuracy, rho = 0.65, p = 0.003; DCCS
switch, rho = 0.52, p = 0.03), good to strong sensitivity
to mental age (flanker accuracy, rho = 0.89, p < 0.001;
DCCS switch, rho = 0.68, p = 0.001), but no associ-
ation with chronological age (all p values >0.20).
Study 2
Feasibility data
Of the 50 participants with FXS and DS seen in study 2,
valid data were obtained from 66 % (list sorting) to 92 %
(picture vocabulary) of the seven NIH-TCB tests (see
Table 2). On review of the test administration notes, the
two most common reasons for missing or invalid data
were inattention and distractibility (e.g., responding in a
valid manner and then losing focus and responding ran-
domly) and lack of understanding of test instructions.
There were a few administrations with technical prob-
lems that made it impossible for participants to main-
tain focus and motivation while problems were being
fixed. A variable indexing the number of tests with suc-
cessful data per participant (range 1–7) was created
and correlated (Spearman’s rho) with chronological and
mental age and with IQ and adaptive behavior compos-
ite scores (when available). Number of successful tests
was significantly correlated with mental age (rho = .47,
p = .001), IQ (rho = .63, p < .001, n = 27) and adaptive
behavior (rho = .42, p = .030, n = 27).
Test-retest reliability and examination of practice effects
Test-retest reliability coefficients and paired sample t
tests comparing performance at baseline and retest are
shown in Table 2. Test-retest reliability ranged from
good (flanker, picture sequence memory, picture vocabu-
lary) to very high (oral reading). Examination of differ-
ences between tests 1 and 2 showed significant practice
effects for pattern comparison and potential practice ef-
fects for picture sequence memory (based on effect size).
Ecological validity
Although domain-specific validation tests were not
available in study 2, examination of correlations with
chronological and mental age were performed, as were
correlations between NIH-TCB measures and adaptive be-
havior and full-scale IQ (18/25 IQ scores were derived
from the Stanford-Binet 5 and 7/25 from the Leiter-R) for
a subgroup of participants. As seen in Table 3, correlations
with chronological age were weak. In contrast, mental age
showed moderate to strong correlations with flanker, oral
reading, and list sorting tests. Full-scale IQ (FSIQ) demon-
strated consistent moderate to strong correlations with
NIH-TCB tasks, and it correlated strongly with the NIH-
TCB cognitive composite. Adaptive behavior was most
strongly correlated with flanker, oral reading, and list sort-
ing, and correlated well with the NIH-TCB composite.
Study 3
Descriptive statistics of gender, caregiver education,
chronological and mental age, IQ, and adaptive behavior
for the DS + ID, FXS + ID, and IID groups for study 3
are shown in Table 4. Primary caregiver education level
was used as a proxy for socioeconomic status. In total,
the participants in study 3 came from highly educated
households with 65.9 % having at least a 4-year degree.
The proportion of males in the FXS + ID and IID groups
was almost twice what we observed in the DS + ID
group. Based on parent/caregiver-report, ten individuals
had a diagnosis of ASD, while three were reported to be
of unknown status. Within the diagnostic groups, four
individuals with FXS + ID and six individuals with IID
were reported to have a diagnosis of ASD.
While the groups had comparable adaptive behavior
composite scores (F(2,41) = 2.19, p = .13) and mean
chronological ages (F(2,41) = .35, p = .70), they differed
significantly by mental age (F(2,41) = 8.30, p = .001) and
Table 2 Study 2 feasibility, test-retest reliability, and examination of practice effects
Feasibility (% of n = 50 valid) Number (test-retest) Visit 1, mean (SD) Visit 2, mean (SD) t p Cohen’s d ICC
DCCS 84 17 3.32 (2.35) 3.89 (2.27) −1.51 .15 .13 .88
Flanker 82 17 4.44 (1.98) 4.33 (2.33) 0.23 .82 .23 .75
List sorting 66 14 9.36 (4.31) 8.00 (4.47) −1.56 .14 .31 .84
Oral reading 90 17 −3.94 (3.18) −3.88 (3.31) 0.71 .49 .03 .99
Pattern comparison 90 16 29.53 (13.47) 35.35 (12.86) 2.08 .01 .44 .90
Picture sequence memory 78 17 −1.39 (0.72) −1.12 (1.05) 1.45 .18 .46 .76
Picture vocabulary 92 17 −2.50 (2.13) −3.05 (1.94) −1.27 .22 .27 .77
Test-retest reliability measured by intraclass correlation (ICC). Practice effects measured by paired samples t tests. Effect size of difference measured by Cohen’s d
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deviation IQ (F(2,42) = 9.69, p < .001). Post hoc compari-
sons using Tukey’s HSD test indicated that the average
mental age and deviation IQ scores were significantly
lower (p < .05) for the FXS + ID and DS + ID groups
compared to the IID group. However, the FXS + ID and
DS + ID groups did not significantly differ from one
another (Table 4).
Feasibility
The proportions of enrolled participants that were able
to understand the NIH-TCB tasks and provide valid
scores are shown in Table 5. For most of the tasks, these
feasibility figures are comparable to children and adoles-
cents from the general population, including DCCS,
flanker, picture vocabulary, oral reading, and picture
sequence memory. For list sorting, slightly more than
half the sample was successful and yielded valid scores.
Although pattern comparison is a relatively simple
task, for which we expected high feasibility figures based
on study 2 (90 %), in this case, only two thirds of the
participants were successful and yielded valid scores.
Upon examination of the practice items and after
reviewing participant response patterns, we noticed that
practice items alternate between “same” and “different”
correct responses. This pattern of alternating responses
from participants often continued throughout the testing
portion of the task, regardless of continued practice and
examiner teaching, whether their responses were correct
or not. Several individuals were either unable to break
the rhythm of this pattern or began to misunderstand
the task.
The number of valid tests completed (0–7) was signifi-
cantly associated with mental age (rho = .70, p < .001)
and deviation IQ (rho = .54, p < .001) but not with
chronological age (rho = −.03, ns) or adaptive behavior
(rho = .29, ns). The most commonly reported reasons
from not obtaining valid data from participants in study
3 were difficulty passing practice items, excessive
prompting during the test portion, refusal to respond,
and questionable understanding. These issues were
somewhat alleviated with the addition of the develop-
mental extension levels for DCCS and flanker made
available about half-way through study 3. Seven partici-
pants were administered the version in which develop-
mental extension items are available. These seven
individuals were between the ages of 8 years, 5 months
and 23 years, 5 months (M = 13.98 ± 6.07). However,
mental age estimates were between 3 years, 6 months
and 6 years (M = 4.51 ± 0.89). Two individuals were diag-
nosed with FXS + ID, one with DS + ID, and the
remaining four were diagnosed with idiopathic ID. Out
of these seven, the developmental extension items were
triggered for four participants on DCCS and three par-
ticipants on flanker. Without the developmental exten-
sions, these tests would not have been quantifiable. A
breakdown of feasibility by mental age level was limited
by small subgroup sample sizes in study 3, but by com-
bining studies 2 and 3 (while acknowledging the









.23 .40** .53** .27
Flanker −.02 .59*** .77*** .59**
Picture vocabulary .32* .22 .38 .26
Oral reading .04 .61*** .71*** .73***
Picture sequence
memory
.03 .14 .44* .44*
Pattern comparison .19 .24 .50** .10
List sorting .28 .54** .61** .50*
NIH-TCB cognitive
composite
– – .75*** .61**
Data shown are Pearson’s correlations. Note: NIH-TCB age-adjusted z
deviation scores were used to correlate with age-adjusted standardized
measures (IQ, adaptive behavior), whereas computed or theta scores
(unadjusted) were used for correlations with mental and chronological age
*p < .05; **p < .01; ***p < .001
aIn study 2, mental age was either the actual mental age generated from
individual IQ tests when test results were available or it was estimated by
the examiner
bIn study 2, IQ scores (Leiter-R or Stanford-Binet 5) were available from prior
recent records in a subset of the sample (n = 25)
Table 4 Study 3 descriptive information by diagnostic group
Total DS + ID FXS + ID IID
n 45 19 10 16
Gender (% male) 71.1 47.4 90.0 87.5
Primary caregiver education (% with at least a 4-year college degree) 65.9 68.4 50.0 73.3
M SD M SD M SD M SD
Chronological age 15.80 5.69 15.01 6.32 16.81 5.73 16.13 5.04
Mental age equivalent (Stanford-Binet 5) 5.24 1.90 4.71 1.42 4.05 0.59 6.53 2.19
Full-scale deviation IQ score (Stanford-Binet 5; [38]) 53.04 17.14 49.76 13.51 40.29 12.92 64.90 16.44
VABS-2 adaptive behavior composite 59.20 16.73 62.58 11.21 49.80 16.82 61.20 20.82
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limitations of mental age estimates in study 2), we had
adequate numbers in each age bin (see Table 6). Feasibil-
ity was good to excellent (≥80 %) for above mental age
of 4 years for all tests except list sorting. For above men-
tal age of 5, more than three quarters of the participants
provided valid data on all tests, and for above mental
age of 7, feasibility was 100 % for the entire battery.
Test-retest reliability and examination of practice
effects For study 3, the reliability statistics were similar
or improved from study 2, with correlations in the mid
.70 to high .90 (see Table 7). The exception was picture
sequence memory with an ICC of .28. This likely
reflected a lack of comparability between parallel forms
A and B. In comparison, study 2 and the normative
studies [59] used the same form A and achieved much
higher correlations. (As such, for group comparsions re-
ported below, we only used data from form A). Aside
from this difference, the test-retest reliability figures ob-
tained in our sample with ID was comparable to those
obtained from children and adolescents from the general
population [59]. No significant differences in perform-
ance between test 1 and test 2 were observed for any of
the NIH-TCB measures in study 3 (all p values >.10),
Table 6 Proportion of participants (%) by mental age group able to complete tests yielding scores judged by examiners and by
data review to be valid (combined studies 2 and 3)
Mental age group Number DCCS Flanker Picture vocabulary Oral reading Picture sequence memory Picture comparison List sorting
3 26 65.4 76.9 88.5 88.5 61.5 69.2 34.6
4 20 85.0 80.0 90.0 90.0 85.0 90.0 50.0
5–6 25 84.0 88.0 92.0 92.0 96.0 84.0 76.0
7–8 12 100.0 100.0 100.0 100.0 100.0 100.0 100.0
9+ 5 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Note that in study 2, mental age was estimated based on chart review and examiner estimation. In study 3, mental age was measured by Stanford-Binet 5
IQ testing
Table 5 Study 3 feasibility, convergent validity, and discriminant validity





ID combined (study 3) Age 3–6, general
populationa
ID combined (study 3) Age 3–6, general
populationa
DCCS 72.2 % 79.8 % −.51* .69*** .65*** .79***
KiTAP flexibility errors WPPSI-III block
design
PPVT-4
Flanker 77.8 % 83.7 % −.61*** .60*** .61*** .67***
KiTAP distractibility WPPSI-III block
design
PPVT-4
Picture vocabularyb 100.0 % 83.7 % .92*** .90*** .53*** .53***
PPVT-4 Leiter-R forward + Spatial
memory z score
BVMT-R + RAVLT
Oral readingb 94.4 % 98.1 % 91*** .96*** .56*** .53***

















List sorting 52.8 % 95.7 % .76*** .57*** .76*** .63***
SB-5 verbal WM NEPSY-II sentence PPVT-4
Validity data shown are Pearson’s correlations
*p < .05; **p < .01; ***p < .001
aZelazo and Bauer [59]
bEstimates reported for the general population are aggregated across the entire child and adolescent sample ranging from 3 to 15 years old
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although it should be emphasized that practice effects
may be seen in larger samples.
Convergent and discriminant validity Validity statistics
of NIH-TCB measures in study 3 and comparison figures
from the general population of children 3–6 years are
shown in Table 5. Note that some validity measures
chosen for each study differ; this should be taken into
account when comparing correlations. In both samples,
the language measures (oral reading and picture vocabu-
lary) demonstrated excellent convergent validity (strong
correlations above .90) and discriminant validity (correla-
tions in the .50 range). The language convergent measures
are very similar in the testing method and differ mainly in
specific item content and time to administer (NIH-TCB
tasks considerably shorter with CAT). The remaining
NIH-TCB tasks showed adequate to good convergent val-
idity with correlation values ranging from −.40 (pattern
comparison raw score with KiTAP go/no-go median RT)
to .76 (list sorting with SB-5 verbal working memory). In
this sample with the chosen measures, discriminant valid-
ity was poor for the remaining NIH-TCB tests. With the
exception of the language measures, the discriminant
validity correlations were equivalent or higher than the
convergent correlations. Limited discriminant validity of
NIH-TCB tests was also reported for children from the
general population normative study [59].
The parent-report convergent validity measures (BRIEF
subscales, SWAN, ABC-C hyperactivity) did not correlate
significantly with analogous NIH-TCB tests (listed in
Table 1). The school-age BRIEF inhibition and the pre-
school BRIEF working memory correlated modestly with
flanker and list sorting; however, the relatively small
sample sizes for these correlations may have limited power
to detect significant associations that may be present.
Ecological validity In the combined sample of individ-
uals with FXS, DS, and IID, the NIH-TCB measures were
strongly associated with mental age and deviation IQ (see
Table 8). Indeed, the correlation between the NIH-TCB
cognitive composite and the SB 5 full-scale deviation IQ
was very strong (0.89; p < .001) and the regression line fell
on the expected standard scores for each measure along









3–15 years, (7–21 days)b
ICC ICC
Dimensional change card sort 27 3.52 (3.46) 4.29 (3.25) −1.31 .20 .25 .74 .92
Flanker 32 4.59 (3.12) 4.38 (3.19) .83 .41 .15 .94 .92
List sorting 26 7.50 (4.11) 8.30 (4.47) -.85 .40 .36 .93 .86
Oral reading 34 901.21 (622.51) 916.91 (604.02) -.29 .78 .05 .93 .97
Pattern comparison 20 28.65 (11.49) 30.08 (13.17) −1.62 .12 .17 .86 .84
Picture sequence memory 30 394.84 (99.23) 404.15 (106.48) -.38 .70 .07 .28a .76
Picture vocabulary 36 914.08 (310.58) 885.14 (294.72) 1.16 .25 .19 .94 .81
Test-retest reliability measured by intraclass correlation (ICC). Practice effects measured by paired samples t tests. Effect size of difference measured by Cohen’s d
aUnlike study 2, alternate forms A and B were used at each visit (random order)
bZelazo and Bauer [59]
Table 8 Study 3 ecological validity
Chronological age Mental age equivalent FSIQ (deviation) Adaptive behavior composite
Dimensional change card sort .31 .72*** .66*** .33
Flanker .27 .61*** .70*** .36*
Picture vocabulary .48** .67*** .70*** .52**
Oral reading .39* .62*** .71*** .42**
Picture sequence memory .34* .55** .57*** .16
Pattern comparison .17 .45* .46** .20
List sorting .57** .49* .52* -.03
NIH-TCB cognitive composite – – .89*** .42*
Data shown are Pearson’s correlations
NIH-TCB age-adjusted z deviation scores were used to correlate with age-adjusted standardized measures (IQ, adaptive behavior), whereas computed or theta
scores (unadjusted) were used for correlations with mental and chronological age
*p < .05; **p < .01; ***p < .001
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most of the continuum of involvement (Fig. 2; e.g., SB-5
IQ of ~40 =NIH-TCB composite ~40). That is, in this
sample, the NIH-TCB composite is a very strong predictor
of FSIQ. Several NIH-TCB measures (DCCS, flanker,
picture vocabulary, and oral reading) were modestly corre-
lated with adaptive behavior, as was the NIH-TCB cogni-
tive composite (r = 0.42, p < .05).
Group/syndrome NIH-TCB differences and profiles
Profiles of age-corrected NIH-TCB z deviation scores
by diagnostic group (as well as the normative study
or general population z scores of zero for compari-
son) are shown in Fig. 3. ANOVAs with group (DS +
ID, FXS + ID, IID) as the independent variable and
each of the NIH-TCB measures as the dependent
variable yielded significant omnibus group effects for
flanker [F(2,74) = 11.09, p < .001], picture vocabulary
[F(2, 79) = 3.24, p = .04], and oral reading [F(2,80) =
7.16, p = .001].
Examination of planned contrasts for flanker demon-
strated that FXS + ID and DS + ID combined had lower
performance than IID [F(1,74) = 6.39, p = .01] and that
FXS + ID performed significantly worse than DS + ID
[F(1,74) = 15.79, p < .001]. The FXS + ID group mean for
flanker was 7 standard deviations below general popula-
tion norms. Furthermore, the effect of diagnostic group
remained significant even when FSIQ was included as a
covariate [F(2, 58) = 14.61, p <.001]. Additionally, when
controlling for FSIQ, the differences observed between
FXS + ID and DS + ID combined compared to the IID
group [F(1, 58) = 10.41, p = .002], as well as those ob-
served between the FXS + ID and DS + ID groups [F(1,
58) = 18.82, p < .001] remained significant. The a priori
hypothesis of deficits on DCCS (cognitive flexibility) for
DS + ID and FXS + ID, compared to IID, was not sup-
ported. Similarly, we hypothesized that individuals with
DS + ID would show greater impairment in episodic
memory as measured by the picture sequence memory
task, however we found no significant group differences
on this task [F(2, 57) = .95, p = .39].
The planned contrast for oral reading showed a signifi-
cant deficit for FXS + ID relative to DS + ID and IID
combined [F(1,80) = 13.17, p = .001]; however, a signifi-
cant strength had been predicted. We also expected to
find better reading performance for the IID group com-
pared to DS+ID group, however our results did not sup-
port this hypothesis [F(1, 80) = 1.15, p = .29]. When
FSIQ was included as a covariate the overall effect of
diagnostic group on oral reading remained significant
[F(2, 61) = 8.01, p < .001]. Additionally, when controlling
for FSIQ, the DS + ID and IID groups together per-
formed significantly better than the FXS + ID group
[F(1, 61) = 13.28, p = .001], and the comparison of the
IID and DS + ID groups remained non-significant [F(1,
61) = 2.73, p = .10] when controlling for FSIQ.
Picture vocabulary detected expected significant rela-
tive deficits for DS + ID compared to IID [F(1,79) = 6.28,
p = .01], but the results did not support the hypothesis
that FXS + ID would perform better than the other two
groups [F(1,79) = .19, p = .67]. Also, the effect of
Fig. 2 Scatterplot showing the association between the NIH-TCB cognitive composite and Stanford-Binet full-scale IQ (z deviation method).
Dotted lines represent the 95 % confidence interval around the regression line. Note that the regression line and correlation (−12.76 + 1.17×; R2 = .79)
show that the composite is a strong predictor of IQ in these samples of individuals with ID
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diagnostic group on picture vocabulary did not remain
significant when FSIQ was included a covariate [F(2, 61)
= 2.34, p =.10]. As hypothesized, there were no signifi-
cant group differences for processing speed [pattern
comparison; F(2, 80) = .52, p = .60]. The highly variable
profiles within groups and across tests relative to test
norms (z = 0, SD = 1 for all tests, Fig. 3) suggest that the
NIH-TCB has potential to detect group and syndromic
cognitive profile differences.
Discussion
In recent years, there has been an increasing pace of dis-
covery of new genetic variants contributing to neurode-
velopmental disorders, advances in the understanding of
the neurobiology and phenotypes of these disorders, and
a plethora of new treatments aiming to normalize brain
neurobiology and improve functioning, with the poten-
tial to reverse cognitive deficits. The vast majority of
clinical trials in FXS and many other disorders associated
with ID have focused on social-emotional treatment tar-
gets including irritability/aggression, anxiety, and aberrant
behavior more broadly. The research effort presented here
to develop and validate cognitive outcome measures does
not detract, or necessarily promote a shift in focus from,
the critical goals of improving social, emotional, and be-
havioral functioning in patients with ID. Rather, it reflects
an impetus to broaden the clinical target options available
to investigators. In the three pilot studies presented here,
we provide supporting evidence of the potential of the
NIH Toolbox Cognitive Battery as outcome measures
for ID, including preliminary results pertaining to
feasibility, reliability, validity, and syndrome-related
cognitive profiles.
Although several tests were feasible for a high propor-
tion of participants (picture vocabulary, pattern com-
parison, oral reading), other measures in their original
form (e.g., list sorting, picture sequence memory) were
less often understandable especially for younger and/or
lower functioning individuals. Given the desire for a bat-
tery applicable to a broad age range and developmental
level, the developmental extensions of tests to a mental
age of 2 years appear to increase feasibility. However, it
is not yet clear whether the easiest items on these exten-
sions measure their intended cognitive construct (for ex-
ample, whether the easiest items of DCCS measure
cognitive flexibility or simply the absence of this ability).
Further, the tablet version of the NIH-TCB appears to
have advantages for this population. For example, most
participants are familiar with how to use and navigate a
tablet from personal experience. Second, it allows more
flexibility in testing positions (e.g., if the participant
needs to move to a better location for testing). Third,
the touch screen response, without the distraction of a
keyboard or mouse, is much simpler and more intuitive.
Fourth, working on the tablet appears more motivating
to many participants. These interpretations are based
mainly on our clinical observations. Although the feasi-
bility figures for the tablet vs. touch screen versions of
Fig. 3 Z scores (±1 SEM) of each NIH-TCB subtest by group. Z scores (age-adjusted) reflect the number of standard deviations from the average
(0 for all subtests) in the normative sample from the general population. For example, the FXS + ID sample had a mean performance on flanker
that is greater than 7 standard deviations below average, adjusted for age. Note that for picture sequence memory, only data from form A
is shown
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the battery are similar, we were stricter with determin-
ation of test administration validity in study 3, so any
improved feasibility of the touch screen method was
difficult to evaluate empirically. Future studies should be
designed to more objectively determine the benefits of
this mode of testing for individuals with ID. The prelim-
inary data presented here suggest that the NIH-TCB
feasibility for ID may increase substantially between
mental ages of 3 and 5 years, although feasibility of the
working memory test (list sorting) is more limited up to
5–6 years. A downward developmental extension of list
sorting would be quite useful.
Test-retest stability across the period of likely treatment
is a critical aspect of measure selection and impacts the
ability to detect real change amid other factors leading to
variability in measurement and impacts required sample
sizes for clinical trials aiming to detect effects of particular
magnitude. All of the NIH-TCB tasks demonstrated good
to excellent test-retest reliability over an approximately a
4-week period. One exception to the strong test-retest sta-
bility of the battery was picture sequence memory (PSM)
in study 3 (ICC = .28); however, in this study, two different
forms (different story “themes”) were administered. Al-
though statistical equivalency of the different forms was
achieved in normative studies of individuals from the gen-
eral population, test-retest reliability across forms was not
reported. In study 2, use of the same PSM form/themes
yielded good reliability and no clear evidence of a practice
effect, although practice effects will require more careful
examination in larger samples. Thus, our data provides
evidence that the scores derived from the different forms
of PSM are probably not equivalent, at least for individuals
with ID. It may be inadvisable to use different forms of
this test in a treatment study until equivalent scores and
adequate test-retest reliability for this population are
established. Also, the test-retest stability of the NIH-TCB
tests substantially beyond 4 weeks cannot be determined
by these results.
Construct validity, through examination of convergent
validity correlations between NIH-TCB tasks and other
measures purporting to tap the same cognitive constructs,
and discriminant validity, aiming to show lower correla-
tions with measures of different constructs, yielded mixed
results in these samples. In study 3, we chose several mea-
sures from the KiTAP to examine convergent validity with
NIH-TCB executive function tasks, based on our prior
studies showing its feasibility, reliability, and validity [49].
However, unlike in our prior work with older patients
enrolled in clinical trials, in this pilot study of younger,
perhaps somewhat lower functioning individuals, we ob-
tained fewer useable data from this test. For the data that
were obtained, convergent validity estimates were very
similar to those obtained in the normative sample of chil-
dren ages 3–6 years [59], suggesting no major falloff in
validity for individuals with ID in these chronological and
mental age ranges. Convergent validity was very good for
picture vocabulary and oral reading, owing in part to
the nearly identical mode of assessment on the NIH-
TCB and validity measures (PPVT-4 and Woodcock-
Johnson word reading). For many tasks, similar to the
data obtained from the normative sample of 3–6-year-
old children, there was little evidence of discriminant
validity. This is likely due to the lack of divergence of
cognitive domains of function in this mental age range,
and the fact that receptive vocabulary (chosen as the
discriminant validity measure for the non-verbal tests)
is highly correlated with g (overall IQ) which is in turn
well correlated with all NIH-TCB tests. In future stud-
ies, it appears essential to utilize alternative measures
that are less strongly associated with g to examine dis-
criminant validity.
The ability of a measure to detect expected cogni-
tive phenotypes and differences is another aspect of
test validity. As executive dysfunction is an exten-
sively documented and prominent aspect of the FXS
phenotype [6–11], the NIH-TCB was successful in meas-
uring substantial inhibitory control and attention deficits
among these participants. Similarly, although the battery
has limited language measures, the picture vocabulary test
did yield lower scores for participants with DS, a group
who has previously been found to score lower on stan-
dardized tests of vocabulary than typically developing
mental age matches [60–64] and individuals with other
forms of ID [62]. Future studies with much larger sample
sizes, and including participants with ID of different eti-
ologies, will further establish the utility of the NIH-TCB
and extend its construct validity.
There are several important limitations of this re-
search. Many of the participants, especially those with
FXS and DS, were patients seen in clinics or were previ-
ously screened and enrolled in clinical trials. While these
individuals may represent the population of individuals
to be studied in clinical research, they may be more af-
fected than the larger populations of these syndromes.
The preliminary studies reported here have focused pri-
marily on feasibility and validity in relatively small sam-
ples; more rigorous work examining the psychometrics
of the NIH-TCB measures in larger samples of individ-
uals with ID are needed before they can be given a
“green light” for use as primary outcomes in clinical tri-
als or other applications. Information on the sensitivity
of these measures to actual changes in cognitive and
daily functioning is needed. Also, the lack of discrimin-
ant validity for some of the measures warrants further
work to determine whether this reflects a weakness in
measurement specificity or a developmentally appropri-
ate lack of differentiation of cognitive skills. Additional
work by other investigators is needed to replicate and
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extend these findings and methodological concepts and
to compare the utility and performance of the NIH-TCB
in ID to other existing measures or other batteries in de-
velopment. Along these lines, collaboration is strongly
encouraged, so that the methods are well standardized
and data are comparable across studies, laboratories,
and clinical populations. This will promote future multi-
site clinical research, which is increasingly essential for
maximizing statistical power to address research ques-
tions about rare NDDs and to generalize results across
cultural and ethnic groups.
The results of the pilot studies were used as a support-
ive evidence for a larger-scale project now underway (“A
Cognitive Test Battery for Intellectual Disabilities”;
R01HD076189). The NIH-TCB for ID is being further
refined and adapted and will be formally validated utiliz-
ing much larger samples (n = 150 per group) of individ-
uals with FXS, DS, and other forms of ID (idiopathic or
various etiologies). Assuming the aims of the project can
be achieved, namely, to show that the NIH-TCB tests
are feasible, reliable, valid, and sensitive to change in in-
dividuals with ID, there are a number of research direc-
tions and questions that can be pursued. The most
obvious application would be to move the tests into clin-
ical trials as outcome measures to track cognitive
changes associated with treatment. This will be the best
way to examine whether the battery, or components of
it, is sensitive to pharmacological or behavioral interven-
tion. This will take time and numerous studies to evalu-
ate its performance in this capacity. Also, some of the
NIH-TCB tasks may be more suitable for use as out-
come measures in clinical trials than others. For ex-
ample, the fluid reasoning measures, such as flanker,
DCCS, and pattern comparison (all of which have a
timed component), and perhaps list sorting and picture
sequence memory, may be more likely to change over a
relatively short treatment period than crystallized mea-
sures of oral reading and picture vocabulary, which re-
flect acquired knowledge. Second, the battery may be
quite useful in developmental/longitudinal studies of
cognitive changes in individuals with ID. Third, given
that several of the tests have established links to brain
functions (working memory/frontal [65, 66]; inhibitory
control/frontostriatal [7]; episodic memory/hippocampus
[67]; processing speed/white matter development [68]),
the battery may aid in understanding the neuropsycho-
logical basis of cognitive impairments in specific syn-
dromic forms of ID, which may in turn lead to more
targeted cognitive interventions. For example, prior work
on the neuropsychological aspects of FXS and DS, espe-
cially deficits in executive functions [9, 10], have led to
trials of computer-based working memory training (see
[69, 70]; “Cognitive Training for Fragile X Syndrome”,
clinicaltrials.gov). The NIH-TCB executive function
tasks might be employed as outcome measures in these
types of cognitive training studies.
Translational research programs in FXS, DS, and other
ID conditions continue to benefit from animal models
which have provided paradigms elucidating neural
mechanisms underlying cognitive and behavioral abnor-
malities. However, as has been seen in the recent FXS
trials, translation from mouse studies to demonstration
of human therapeutic benefits has been extremely chal-
lenging. We suspect that phenotypes of Fmr1 knockout
mice may differ phenomenologically and mechanistically
from that of human patients. For example, “anxiety” or
“memory” as measured by the elevated plus and Morris
water mazes, respectively, may differ substantially from
mechanisms and contextual expression of such problems
in humans with FXS. A critical goal for the translational
efforts in ID going forward is to establish measures
across species that share the same or similar neurobio-
logical mechanisms. In this way, candidate drugs can be
compared across species with more confidence that they
are acting on the same pathways. In this regard, it is
noteworthy that cognitive tasks developed for mice,
including measures of attention, inhibitory control,
working and object memory, and pattern discrimination
using touch screen technology [71–74], are available and
could in the future be compared across species with
some of the NIH-TCB tasks. This should facilitate trans-
lation of findings from animal to human studies and will
maximize the potential for the discovery of truly disease-
modifying interventions.
Conclusions
The three preliminary studies reported here provide the
first psychometric support for the utility of the NIH
Toolbox Cognitive Battery for individuals with ID, a
population that has historically posed significant chal-
lenges for clinicians and investigators to develop feasible
and valid cognitive outcome measures. With forthcom-
ing larger-scale validation, this battery has potential to
facilitate the detection of cognitive changes associated
with pharmacological and behavioral interventions with
web-based technology that is scalable and reliable across
multi-site studies.
Acknowledgements
We thank Rebekah Abel, Lee Ann Baer, Edmond Bedjeti, Erin Carmody, Jamie
Edgin, Randi Hagerman, Crystal Hervey, Ethan Hessl, Francis Hickey, Maria
Kharitonova, Forrest McKenzie, Ashwini Mulgaonkar, Cindy Nowinski, Bruce
Pennington, Melanie Rothfuss, Merve Senalan, Rebecca Shields, Madeleine
Schloetter, Nicole Tartaglia, Talia Thompson, Jamie Woods, Philip Zelazo, and
the many families participating in the studies for their dedication, time, and effort.
Funding
This work was supported by a National Institute of Child Health and Human
Development grant (R01 HD076189 to DH, KR, EBK, and RG), the MIND
Institute Intellectual and Developmental Disabilities Research Center (U54
HD079125 to LA), a grant from the Fragile X Community Support Network
Hessl et al. Journal of Neurodevelopmental Disorders  (2016) 8:35 Page 16 of 18
Group of Greater Chicago through the National Fragile X Foundation (to
EBK), the Office of the Dean at the UC Davis School of Medicine (to DH), and
the Rush University Medical Center (Dean’s Summer Student Fellowship to
DO). This publication was also made possible by grant UL1 TR000002 and
linked awards TL1 TR000133, UL1 TR000153, and UL1 TR001414 from the
National Center for Advancing Translational Sciences, NIH, through the
Biostatistics, Epidemiology, and Research Design Unit.
Availability of data and materials
The de-identified data collected for the analysis in these preliminary studies
are available on request to the corresponding author (DH).
Authors’ contributions
DH conceived the overall project, obtained primary funding, directed the
studies, and authored the manuscript. SMS coordinated all aspects of study
3, analyzed all data from studies 2 and 3, and authored portions of the
manuscript. EBK directed studies 2 and 3 at Rush University and critically
reviewed the manuscript. KR directed study 3 at the University of Denver
and critically reviewed the manuscript. KW supervised and directed all
statistical analyses and designed the analysis plan for the project. LA
authored portions of the manuscript and critically reviewed the manuscript.
AS completed cognitive testing of participants in studies 1 and 2 and
critically reviewed the manuscript. JC supervised all cognitive assessments at
the University of Denver for study 3. KR and DO collected all cognitive data
at the Rush University in studies 2 and 3. RG is the PI and director of the NIH
Toolbox for Assessment of Neurological and Behavioral Function, directed all
Toolbox Cognitive Battery activities for the studies, and critically reviewed
the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All participants or their legal guardians gave consent for their de-identified
data to be published.
Ethics approval and consent to participate
The studies were approved by the Institutional Review Boards of the UC
Davis (#681782), Rush University Medical Center (#14021002), and University
of Denver (#698133). All participants or their legal guardians gave written
consent to participate in the research, and capable participants gave their
written consent or assent as determined by the IRBs.
Author details
1Translational Psychophysiology and Assessment Laboratory (T-PAL), MIND
Institute, UC Davis Medical Center, Sacramento, CA, USA. 2Department of
Psychiatry and Behavioral Sciences, University of California Davis Medical
Center, Sacramento, CA, USA. 3Department of Pediatrics, University of
California Davis Medical Center, Sacramento, CA, USA. 4Department of
Pediatrics, Rush University Medical Center, Chicago, IL, USA. 5Department of
Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
6Department of Biochemistry, Rush University Medical Center, Chicago, IL,
USA. 7School of Medicine, Rush University Medical Center, Chicago, IL, USA.
8Morgridge College of Education, The University of Denver, Denver, CO, USA.
9Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
10Graduate School of Education, University of California Riverside, Riverside,
CA, USA.
Received: 14 June 2016 Accepted: 11 August 2016
References
1. Goldberg EM. Are the majority of children with autism mentally retarded: a
systematic evaluation of the data. Focus Autism Dev Dis. 2011;21(2):66–83.
2. de Vries PJ. Targeted treatments for cognitive and neurodevelopmental
disorders in tuberous sclerosis complex. Neurotherapeutics. 2010;7(3):275–82.
3. Dolen G, Bear MF. Role for metabotropic glutamate receptor 5 (mGluR5) in
the pathogenesis of fragile X syndrome. J Physiol. 2008;586(6):1503–8.
4. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, et al.
Correction of fragile X syndrome in mice. Neuron. 2007;56(6):955–62.
5. Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka RC, et al.
Pharmacotherapy for cognitive impairment in a mouse model of Down
syndrome. Nat Neurosci. 2007;10(4):411–3.
6. Cornish K, Munir F, Wilding J. [A neuropsychological and behavioural profile
of attention deficits in fragile X syndrome]. Rev Neurol. 2001;33 Suppl 1:S24–29.
7. Menon V, Leroux J, White CD, Reiss AL. Frontostriatal deficits in fragile X
syndrome: relation to FMR1 gene expression. Proc Natl Acad Sci U S A.
2004;101(10):3615–20.
8. Hessl D, Berry-Kravis E, Cordeiro L, Yuhas J, Ornitz EM, Campbell A, et al.
Prepulse inhibition in fragile X syndrome: feasibility, reliability, and
implications for treatment. Am J Med Genet B Neuropsychiatr Genet. 2009;
150B(4):545–53.
9. Wilding J, Cornish K, Munir F. Further delineation of the executive deficit in
males with fragile-X syndrome. Neuropsychologia. 2002;40(8):1343–9.
10. Munir F, Cornish KM, Wilding J. A neuropsychological profile of attention
deficits in young males with fragile X syndrome. Neuropsychologia. 2000;
38(9):1261–70.
11. Scerif G, Cornish K, Wilding J, Driver J, Karmiloff-Smith A. Delineation of early
attentional control difficulties in fragile X syndrome: focus on
neurocomputational changes. Neuropsychologia. 2007;45(8):1889–98.
12. Dykens EM, Hodapp RM, Leckman JF. Strengths and weaknesses in the
intellectual functioning of males with fragile X syndrome. Am J Ment Defic.
1987;92(2):234–6.
13. Mazzocco MM. Math learning disability and math LD subtypes: evidence
from studies of Turner syndrome, fragile X syndrome, and
neurofibromatosis type 1. J Learn Disabil. 2001;34(6):520–33.
14. Mazzocco MM, Singh Bhatia N, Lesniak-Karpiak K. Visuospatial skills and their
association with math performance in girls with fragile X or Turner
syndrome. Child Neuropsychol. 2006;12(2):87–110.
15. Rivera SM, Menon V, White CD, Glaser B, Reiss AL. Functional brain
activation during arithmetic processing in females with fragile X syndrome
is related to FMR1 protein expression. Hum Brain Mapp. 2002;16(4):206–18.
16. Abbeduto L, Brady N, Kover ST. Language development and fragile X
syndrome: profiles, syndrome-specificity, and within-syndrome differences.
Ment Retard Dev Disabil Res Rev. 2007;13(1):36–46.
17. D'Hulst C, Kooy RF. The GABAA receptor: a novel target for treatment of
fragile X? Trends Neurosci. 2007;30(8):425–31.
18. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman
RJ, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is
associated with differential response to the mGluR5 antagonist AFQ056. Sci
Transl Med. 2011;3(64):64ra61.
19. Berry-Kravis E, Des Portes V, Hagerman R, Jacquemont S, Charles P, Visootsak
J, et al. Mavoglurant in fragile X syndrome: results of two randomized,
double-blind, placebo-controlled trials. Sci Transl Med. 2016;8(321):321ra325.
20. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen
K, et al. Effects of STX209 (Arbaclofen) on neurobehavioral function in
children and adults with fragile X syndrome: a randomized, controlled,
phase 2 trial. Sci Transl Med. 2012;4(152):152ra127.
21. Berry-Kravis E, Hagerman RJ, Visootsak J, Budimirovic D, Kaufmann WE,
Walton-Bowen K et al. Arbaclofen in fragile X syndrome: results of phase 3
trials. Journal of Neurodevelopmental Disorders. In review.
22. Johnston C, Hessl D, Blasey C, Eliez S, Erba H, Dyer-Friedman J, et al. Factors
associated with parenting stress in mothers of children with fragile X
syndrome. J Dev Behav Pediatr. 2003;24(4):267–75.
23. Hessl D, Dyer-Friedman J, Glaser B, Wisbeck J, Barajas RG, Taylor A, et al. The
influence of environmental and genetic factors on behavior problems and
autistic symptoms in boys and girls with fragile X syndrome. Pediatrics.
2001;108(5):E88.
24. Estes A, Munson J, Dawson G, Koehler E, Zhou XH, Abbott R. Parenting
stress and psychological functioning among mothers of preschool children
with autism and developmental delay. Autism. 2009;13(4):375–87.
25. Roizen NJ, Patterson D. Down's syndrome. Lancet. 2003;361(9365):1281–9.
26. Pennington BF, Moon J, Edgin J, Stedron J, Nadel L. The neuropsychology
of Down syndrome: evidence for hippocampal dysfunction. Child Dev. 2003;
74(1):75–93.
27. Edgin JO, Kumar A, Spano G, Nadel L. Neuropsychological effects of second
language exposure in Down syndrome. J Intellect Disabil Res. 2011;55(3):
351–6.
28. Edgin JO, Mason GM, Allman MJ, Capone GT, Deleon I, Maslen C, et al.
Development and validation of the Arizona Cognitive Test Battery for Down
syndrome. J Neurodev Disord. 2010;2(3):149–64.
Hessl et al. Journal of Neurodevelopmental Disorders  (2016) 8:35 Page 17 of 18
29. Zelazo PD, Burack JA, Benedetto E, Frye D. Theory of mind and rule use in
individuals with Down's syndrome: a test of the uniqueness and specificity
claims. J Child Psychol Psychiatry. 1996;37(4):479–84.
30. Lanfranchi S, Jerman O, Dal Pont E, Alberti A, Vianello R. Executive function
in adolescents with Down syndrome. J Intellect Disabil Res. 2010;54(4):308–19.
31. Visu-Petra L, Benga O, Tincas I, Miclea M. Visual-spatial processing in
children and adolescents with Down's syndrome: a computerized
assessment of memory skills. J Intellect Disabil Res. 2007;51(Pt 12):942–52.
32. Dunst CJ. Stage transitioning in the sensorimotor development of Down's
syndrome infants. J Ment Defic Res. 1988;32(Pt 5):405–10.
33. Fidler DJ, Philofsky A, Hepburn SL, Rogers SJ. Nonverbal requesting and
problem-solving by toddlers with down syndrome. Am J Ment Retard.
2005;110(4):312–22.
34. Kasari C, Freeman SF. Task-related social behavior in children with Down
syndrome. Am J Ment Retard. 2001;106(3):253–64.
35. Fernandez F, Garner CC. Episodic-like memory in Ts65Dn, a mouse model of
Down syndrome. Behav Brain Res. 2008;188(1):233–7.
36. Reiss AL, Dant CC. The behavioral neurogenetics of fragile X syndrome:
analyzing gene-brain-behavior relationships in child developmental
psychopathologies. Dev Psychopathol. 2003;15(4):927–68.
37. Hessl D, Nguyen DV, Green C, Chavez A, Tassone F, Hagerman RJ, et al. A
solution to limitations of cognitive testing in children with intellectual
disabilities: the case of fragile X syndrome. J Neurodev Disord. 2009;1(1):33–45.
38. Sansone SM, Schneider A, Bickel E, Berry-Kravis E, Prescott C, Hessl D.
Improving IQ measurement in intellectual disabilities using true deviation
from population norms. J Neurodev Disord. 2014;6(1):16.
39. Weintraub S, Dikmen SS, Heaton RK, Tulsky DS, Zelazo PD, Bauer PJ, et al.
Cognition assessment using the NIH Toolbox. Neurology. 2013;80(11 Suppl
3):S54–64.
40. Gershon RC, Cella D, Fox NA, Havlik RJ, Hendrie HC, Wagster MV.
Assessment of neurological and behavioural function: the NIH Toolbox.
Lancet Neurol. 2010;9(2):138–9.
41. Weintraub S, Bauer PJ, Zelazo PD, Wallner‐Allen K, Dikmen SS, Heaton RK,
Havlik RJ. I. NIH toolbox cognition battery (CB): Introduction and pediatric
data. Monogr Soc Res Child Dev. 2013;78(4):1–15.
42. Zelazo PD, Anderson JE, Richler J, Wallner-Allen K, Beaumont JL, Weintraub
S. NIH Toolbox Cognitive Function Battery (CFB): measuring executive
function and attention. Child Dev. 2013;78(4):16–33.
43. Weintraub S, Bauer PJ, Zelazo PD, Wallner-Allen K, Dikmen SS, Heaton RK,
et al. I. NIH Toolbox Cognition Battery (CB): introduction and pediatric data.
Monogr Soc Res Child Dev. 2013;78(4):1–15.
44. Zelazo PD, Anderson JE, Richler J, Wallner-Allen K, Beaumont JL, Weintraub
S. II. NIH Toolbox Cognition Battery (CB): measuring executive function and
attention. Monogr Soc Res Child Dev. 2013;78(4):16–33.
45. Bauer PJ, Dikmen SS, Heaton RK, Mungas D, Slotkin J, Beaumont JL. III. NIH
Toolbox Cognition Battery (CB): measuring episodic memory. Monogr Soc
Res Child Dev. 2013;78(4):34–48.
46. Tulsky DS, Carlozzi NE, Chevalier N, Espy KA, Beaumont JL, Mungas D. V. NIH
Toolbox Cognition Battery (CB): measuring working memory. Monogr Soc
Res Child Dev. 2013;78(4):70–87.
47. Carlozzi N, Tulsky DS, Kail RV, Beaumont JL. NIH Toolbox Cognitive Function
Battery (CFB): measuring processing speed. Child Dev. 2013;78(4):88–102.
48. Gershon R, Slotkin J, Manly J, Blitz D, Beaumont JL, Schnipke D, et al. NIH
Toolbox Cognitive Function Battery (CFB): measuring language (vocabulary
comprehension and reading decoding). Child Dev. 2013;78(4):49–69.
49. Knox A, Schneider A, Abucayan F, Hervey C, Tran C, Hessl D, et al. Feasibility,
reliability, and clinical validity of the Test of Attentional Performance for
Children (KiTAP) in fragile X syndrome (FXS). J Neurodev Disord. 2012;4(1):2.
50. Dunn LM, Dunn DM. Peabody Picture Vocabulary Test. 4th ed. San Antonio:
Pearson; 2007.
51. Woodcock R, Johnston MEB. Woodcock-Johnson Tests of Achievement.
Fourth ed. Itasca, IL: Riverside Publishing; 2014.
52. Roid GH, Miller LJ. Leiter International Performance Scale, Revised. Wood
Dale: Stoetling; 1997.
53. Roid GH. Stanford-Binet Intelligence Scales. Fifth Edition. San Antonio:
Pearson; 2003.
54. Aman M, Singh N, Stewart A, Field C. The Aberrant Behavior Checklist: a
behavior rating scale for the assessment of treatment effects. Am J Ment
Defic. 1985;89:485–91.
55. Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating inventory of
executive function. Child Neuropsychol. 2000;6(3):235–8.
56. Swanson JM, Schuck S, Porter MM, Carlson C, Hartman CA, Sergeant JA,
et al. Categorical and dimensional definitions and evaluations of symptoms
of ADHD: history of the SNAP and the SWAN rating scales. Int J Educ
Psychol Assess. 2012;10(1):51–70.
57. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap)—a metadata-driven methodology and
workflow process for providing translational research informatics support.
J Biomed Inform. 2009;42(2):377–81.
58. Akshoomoff N, Beaumont JL, Bauer PJ, Dikmen SS, Gershon RC, Mungas D,
et al. VIII. NIH Toolbox Cognition Battery (CB): composite scores of
crystallized, fluid, and overall cognition. Monogr Soc Res Child Dev. 2013;
78(4):119–32.
59. Zelazo PD, Bauer PJ. National Institutes of Health Toolbox—Cognitive
Function Battery (NIH Toolbox CFB): validation for children between 3 and
15 years: child development. Monographs of the society for research in
child development. 2013;78(4):1–172.
60. Caselli MC, Monaco L, Trasciani M, Vicari S. Language in Italian children with
Down syndrome and with specific language impairment. Neuropsychology.
2008;22(1):27–35.
61. Hick RF, Botting N, Conti-Ramsden G. Short-term memory and vocabulary
development in children with Down syndrome and children with specific
language impairment. Dev Med Child Neurol. 2005;47(8):532–8.
62. Loveall SJ, Channell MM, Phillips BA, Abbeduto L, Conners FA. Receptive
vocabulary analysis in Down syndrome. Res Dev Disabil. 2016;55:161–72.
63. Price J, Roberts J, Vandergrift N, Martin G. Language comprehension in boys
with fragile X syndrome and boys with Down syndrome. J Intellect Disabil
Res. 2007;51(Pt 4):318–26.
64. Roberts JE, Price J, Malkin C. Language and communication development in
Down syndrome. Ment Retard Dev Disabil Res Rev. 2007;13(1):26–35.
65. Kwon H, Menon V, Eliez S, Warsofsky IS, White CD, Dyer-Friedman J, et al.
Functional neuroanatomy of visuospatial working memory in fragile X
syndrome: relation to behavioral and molecular measures. Am J Psychiatry.
2001;158(7):1040–51.
66. Bunge SA, Klingberg T, Jacobsen RB, Gabrieli JD. A resource model of the
neural basis of executive working memory. Proc Natl Acad Sci U S A. 2000;
97(7):3573–8.
67. Bauer PJ. Toward a neuro-developmental account of the development of
declarative memory. Dev Psychobiol. 2008;50(1):19–31.
68. Mabbott DJ, Noseworthy M, Bouffet E, Laughlin S, Rockel C. White matter
growth as a mechanism of cognitive development in children. Neuroimage.
2006;33(3):936–46.
69. Bennett SJ, Holmes J, Buckley S. Computerized memory training leads to
sustained improvement in visuospatial short-term memory skills in children
with Down syndrome. Am J Intellect Dev Disabil. 2013;118(3):179–92.
70. Au J, Berkowitz-Sutherland L, Schneider A, Schweitzer J, Hessl D, Hagerman
RJ. A feasibility trial of Cogmed working memory training in fragile X
syndrome. J Pediatric Gen. 2014;3:147–56.
71. Brigman JL, Bussey TJ, Saksida LM, Rothblat LA. Discrimination of
multidimensional visual stimuli by mice: intra- and extradimensional shifts.
Behav Neurosci. 2005;119(3):839–42.
72. Brigman JL, Graybeal C, Holmes A. Predictably irrational: assaying cognitive
inflexibility in mouse models of schizophrenia. Front Neurosci. 2010;4:13.
73. Bussey TJ, Holmes A, Lyon L, Mar AC, McAllister KA, Nithianantharajah J,
et al. New translational assays for preclinical modelling of cognition in
schizophrenia: the touchscreen testing method for mice and rats.
Neuropharmacology. 2012;62(3):1191–203.
74. Bussey TJ, Padain TL, Skillings EA, Winters BD, Morton AJ, Saksida LM. The
touchscreen cognitive testing method for rodents: how to get the best out
of your rat. Learn Mem. 2008;15(7):516–23.
Hessl et al. Journal of Neurodevelopmental Disorders  (2016) 8:35 Page 18 of 18
